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0 The Journal of Thoracic and Cardiovbjective: Choice of a mechanical or biologic valve in aortic valve replacement remains
ontroversial and rotates around different complications with different time-related
ncidence rates. Because serious complications will always “spill over” into mortality,
ur aim was to perform a meta-analysis on overall mortality after aortic valve replace-
ent from series with a maximum follow-up of at least 10 years to determine the age-
nd risk factor-corrected impact of currently available mechanical versus stented bio-
rosthetic valves.
ethods: Following a formal study protocol, we performed a dedicated literature search
f publications during 1989 to 2004 and included articles on adult aortic valve replace-
ent with a mechanical or stented bioprosthetic valve if age, mortality statistics, and
revalences of well-known risk factors could be extracted. We used standard and robust
egression analyses of the case series data with valve type as a fixed variable.
esults: We could include 32 articles with 15 mechanical and 23 biologic valve series
otaling 17,439 patients and 101,819 patient-years. The mechanical and biologic valve
eries differed in regard to mean age (58 vs 69 years), mean follow-up (6.4 vs 5.3 years),
oronary artery bypass grafting (16% vs 34%), endocarditis (7% vs 2%), and overall
eath rate (3.99 vs 6.33 %/patient-year). Mean age of the valve series was directly
elated to death rate with no interaction with valve type. Death rate corrected for age,
ew York Heart Association classes III and IV, aortic regurgitation, and coronary artery
ypass grafting left valve type with no effect. Included articles that abided by current
uidelines and compared a mechanical and biologic valve found no differences in rates
f thromboembolism.
onclusion: There was no difference in risk factor-corrected overall death rate between
echanical or bioprosthetic aortic valves irrespective of age. Choice of prosthetic valve
hould therefore not be rigorously based on age alone. Risk of bioprosthetic valve
egeneration in young and middle-aged patients and in the elderly and old with a long
ife expectancy would be an important factor because risk of stroke may primarily be
elated to patient factors.
hoice of a prosthetic heart valve in aortic valve replacement (AVR) remains
controversial. Current guidelines recommend a mechanical valve in patients
aged less than 65 years, but this is based on class II evidence (conflicting
vidence or opinion).1 The only class I evidence is for choosing a mechanical valve
n patients with an expected long life span,1 which may be gaining increasing
ignificance for 2 reasons. First, life expectancy is increasing in the general popu-
ation in the industrialized world, for instance, to 17 years for a 65-year-old white
an in the United States in 2002.2 Second, life expectancy calculations in the
eneral population include mortality from chronic debilitating or fatal diseases (eg,
ementia and cancer), which are prevalent in the elderly and which contraindicate
alve replacement. Even patients aged more than 70 years may achieve normal or
onger than average life expectancy after AVR.3-5 Long life spans may make
ascular Surgery ● July 2006
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CDtructural valve degeneration (SVD) of a bioprosthetic valve
lmost inevitable in the elderly.5,6
Recent years have nonetheless witnessed a shift in pros-
hetic heart valve preference from mechanical to biologic
alves, which is not just explained by the increasing age of
atients. Bioprosthetic valves are increasingly being im-
lanted in younger patients7 spurred by the belief that
hird-generation stented xenografts have superior durability
ompared with previous models.E1 The risk of SVD accel-
rates with time (ie, requires long follow-up to become
pparent) and is inversely related to age.6 High SVD rates of
arlier models implanted in younger patients through the
970s and 1980s resulted in a high proportion of redo AVR
ausing the preference to swing back toward mechanical
alves. Our knowledge base on SVD of third-generation
enografts is consequently based predominantly on valve
eries with too few young patients who underwent operation
oo late in the series to have an impact at the present time.
xtrapolation from seemingly low rates of SVD in current
elatively short “old age series” to younger patients may
hus be in error.
Thromboembolism and anticoagulant-related bleeding
emain the dominant complications of mechanical valves.
he incidence rates of these complications seem to be fairly
onstant after AVR, but reported rates vary considerably
specially for bioprosthetic valves including rates of zero or
elow the age-specific stroke rates of the background pop-
lation.6,8 Meta-analysis of published data taking both death
nd the main prosthesis-related complications into account
o assess the benefits of mechanical versus biologic
alves9-11 may thus be misleading. Previous meta-analyses
ave, furthermore, included series with obsolete mechanical
alves9,10 and bioprosthetic valve series with follow-up of
ess than 10 years with related low SVD rates.10,11 Finally,
eta-analyses have been coupled with microsimulation,
hich is difficult to comprehend and for which the chosen
odeling parameters may introduce bias.9,11
A death is an extremely well-defined event, and it would
ake common sense to postulate that a prosthetic valve
omplication entity that does not impact mortality of the
atients is merely trivial, and none of them are. We there-
Abbreviations and Acronyms
AC  anticoagulation
AVR  aortic valve replacement
CL  confidence limit
INR  international normalized ratio
NYHA New York Heart Association
SD  standard deviation
SVD  structural valve degenerationore had as our primary aim to perform a meta-analysis on e
The Journal of Thoracertinent publications from 1989 to 2004 to determine the
ge-corrected impact of currently available mechanical
bileaflet and single disc) versus stented bioprosthetic (por-
ine and bovine pericardial) valves on crude mortality after
VR and to correct for the impact of other well-known risk
actors using standard and robust regression analysis tech-
iques. To minimize bias related to mortality of various
omplications with peculiar time effects, which may differ
etween mechanical and biologic valves, we chose to in-
lude only publications with a maximum follow-up of at
east 10 years.
aterials and Methods
e followed a predetermined formal study protocol as suggested
y methodologic guidelines for observational studies.12 Our pri-
ary effect variable was overall death rate. We performed a
edicated literature search of MEDLINE using 2 search engines:
ubMed of the US National Library of Medicine and the European
MBASE. We used a broad Boolean search string: “(aorta OR
ortic) AND valve AND replacement AND (survival OR mortality
R death rate OR hazard rate),” thus avoiding exclusion terms that
ould cause articles of interest to be overlooked. We chose articles
n English published between 1989 and 2004 because 10-year
esults with most currently available prosthetic heart valves did not
ppear earlier. PubMed and EMBASE yielded 2007 and 1954 hits,
espectively, and these publications were scrutinized according to
he criteria given below.
nclusion and Exclusion Criteria and Essential Data
xtraction
rticles were included if essential data (defined below) could be
xtracted from a pure mechanical or stented bioprosthetic AVR
eries with a longest follow-up of at least 10 years, with at least 75
atients and a maximum of 5% aged less than 15 years, and with
urrently available prosthetic valves. We accepted up to 10%
bsolete valve types in mixed mechanical or biologic valve series
nd excluded articles in which the operative period started before
975 to avoid time bias. We included only articles that claimed
onformance to either the original13 or current14 guidelines for
eporting (or that detailed comparable definitions and method of
ollow-up), had at most 5% of patients lost to follow-up,13,14 and
riginated in the industrialized world (Appendix E1). To avoid
onfounding between case series by factors not related to AVR per
e, we excluded series with prevalences of redo operations, con-
omitant surgery other than coronary artery bypass grafting
CABG), and operation for active endocarditis of more than 20%.
t was essential that we could extract the following data: (1) Death
tatistics: total number of deaths (early and late) of any cause and
otal follow-up (accumulated number of patient-years). (2) Demo-
raphic and operative data: mean age of the patients with standard
eviation or range; prevalence of women, concomitant CABG,
oncomitant other procedures, redo operation, and operation for
ctive endocarditis. (3) A measure of disease severity: We chose
ew York Heart Association (NYHA) functional classes because
hey are usually reported. Other “disease severity” variables in-
luding left ventricular function and comorbidities could only be
xtracted from a fraction of the included articles (Appendix E1).
ic and Cardiovascular Surgery ● Volume 132, Number 1 21
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CD4) Valve disease: Prevalence of aortic stenosis, regurgitation, and
ixed lesion could be recorded in all but 1 of the included articles.
pecific exclusion criteria are given per inference from the above.
e also excluded pure specialty articles, such as those on the small
ortic root/small-sized prosthetic valves and so forth. In case of
epeat publications from the same institution, we chose the last
ublished or the one from which the essential data could be
xtracted. Further details are given in Appendix E1. In total we
ere able to include 32 articlesE1-E32 with 38 valve series, which
re detailed in Table E1 relative to valve type.
tatistical Analysis
ll analyses were performed with Stata 8 (Stata Corporation,
ollege Station, Tex).15 The strategy was to use overall death rate
s the outcome variable in a regression, with valve type as a fixed
redictor and other significant predictors including mean age of the
alve series added to remove confounding and reduce variability.
he overall mortality rate has the advantage of using the whole of
he data; every year of observation of a patient is included. It gives
ll deaths equal weight, except that that early deaths reduce the
umber of years of follow-up, as well as increase the number of
eaths. Because the focus of the investigation was comparison
etween mechanical and bioprosthetic valve types and this bias
ill be present in all series, it should have little if any effect on
ifferences. Two regression methods were used: least squares
inear regression with death rate as the dependent variable, and
egative binomial regression with number of deaths as the depen-
ent variable and patient-years at risk as the exposure variable. We
ncluded the latter for comparison because it has been used in
imilar studies.16 We cannot treat study (or article) as a fixed
ABLE 1. Pertinent demographic, preoperative, and operat
ioprosthetic valve series
Mechanical valve series
o. of patients 8578 (93-1755)
otal follow-up (patient-y) 54,538 (383-9302
ean follow-up (y) 6.4 (3.9-10.8)
otal No. of deaths 2178 (15-375)
ength of operation period (y) 16.2 (5-25)
ean age (y) 58.0 (48-75)
omen (%) 34.5 (21-54)
YHA classes III and IV (%) 64.6 (29-92)
ortic regurgitation (%) 28.7 (8-48)
ortic stenosis (%) 50.9 (22-72)
ctive endocarditis (%) 6.8 (0-11)
oncomitant CABG (%) 15.7 (0-57)
ther concomitant
procedures (%)
4.5 (0-20)
edo operation (%) 3.8 (0-10)
eath rate (%/patient-y) 3.99 (1.52-8.88
YHA, New York Heart Association’s functional classification; CABG, coron
Missing in one series (E22). Data are total number of patients, total follow-
n parentheses. Mean age, mean follow-up, and length of operation period a
ith range of individual series in parentheses. Death rate is rate of all ac
ith range of individual series in parentheses.actor, because most studies include only 1 series. We therefore v
2 The Journal of Thoracic and Cardiovascular Surgery ● July 2dopted a random-effects approach, treating each study as a cluster
nd using robust standard errors using the Huber-White-sandwich
stimator of variance.15 Further details of the statistical analyses
re given in Appendix E2.
esults
he 32 articles provided 38 case series with a total of 17,439
atients and 101,819 patient-years. The maximum follow-up
eriod in a series varied between 10 and 25 years. There were
total of 5170 deaths (936 early and 4234 late). Operations
ere performed between 1975 and 2002. Table 1, Appendix
1, and Table E1 detail the variables that could be extracted
rom the 15 mechanical and 23 bioprosthetic valve series. The
echanical valve series were on average larger with longer
ollow-up and had lower weighted (by total number of patients
n each series) mean age and prevalence of CABG but higher
revalence of operation for active endocarditis than the bio-
ogic valve series. There was a large difference in mean age
istribution between mechanical and biologic valve series but
ith a considerable overlap (Figure 1). Adjusting for an age
mpact on mortality without obscuring any real effect should
hus be possible.
All variables (Table 1, Appendix E1) were screened for an
ssociation with death rate. Patients with mechanical valves
ad significantly lower mortality than patients with biologic
alves (P  .0001). Mean age was strongly related to death
ate (P  .0001; Figure 2). Adjustment for age eliminated the
ata; follow-up; and death rates from the mechanical and
15) Biologic valve series (N  23) P value*
8861 (75-1108) .1
47,281 (349-5093) .008
5.3 (2.6-10.1) .05
2992 (25-416) .6
12.5 (3-20) .04
68.8 (50-77) .001
37.5 (15-57) .3
69.6 (49-94) .3
16.5 (23-57)† .001
68.6 (21-100)† .002
2.2 (0-5) .001
34.1 (0-100) .006
7.2 (0-16) .2
5.0 (0-15) .2
6.33 (1.77-9.09) .001
rtery bypass grafting. *Two-sample t test weighted by number of patients.
d total number of deaths of included series with range of individual series
l as prevalences (%) are weighted by number of patients in included series
lated deaths of included series in relation to total accumulated follow-upive d
(N 
)
)
ary a
up, an
s wel
cumualve type effect (P  .8). To examine whether there was an
006
i
a
i
(
w
n
r
m
C
s
L
W
n
a
t
l
(
f
t
1

N
T
e
C
r
e
r
t
g

b
D
T
t
t
F
m
s
v
F
b
s
l
T
P
M
H
N
A
C
C
*
r
t
with mean age of individual valve series. ‡Entered into model with prevalence
Lund and Bland Surgery for Acquired Cardiovascular Disease
The Journal of Thorac
A
CDnteraction between valve type and age we modeled an inter-
ction term in the least squares regression model by multiply-
ng mean age by 0 for mechanical valve and by 1 for biologic
and vice versa); this enables the slope of the age relationship
ith death rate to be different for the 2 valve types, which was
ot significant (P  .50). When corrected for age in the
egression model each of the following variables individually
aintained a significant effect on death rate: concomitant
ABG, NYHA classes III and IV, aortic regurgitation, aortic
tenosis, and active endocarditis.
east Squares Regression Analysis of Death Rate
e kept valve type and mean age in the model and elimi-
ated the other potentially significant risk factors identified
bove one by one in order of the highest P value greater
han .05. Mean age remained the strongest risk factor fol-
owed by NYHA classes III and IV, and aortic regurgitation
Table 2). After correction for the impact of these risk
actors the estimated difference in death rates between valve
ypes (biologic minus mechanical) was 0.23 deaths per
00 patient-years (95% confidence limit [CL]: 0.99 to
0.63, P  .5).
egative Binomial Regression Analysis of Death Rate
he final model included age and CABG (Table 2). The
stimated rate ratio (biologic/mechanical) was 0.94 (95%
L 0.79-1.10, P  .4). To compare the results of the
egression analyses we converted the death rate difference
stimates from the least squares regression analysis into a
atio; we took the overall weighted mean death rate, added
he valve effect, and then divided by the overall rate. This
ave an estimated rate ratio of 0.95 (95% CL 0.81-1.10, P
.5), which is similar to the ratio from the negative
inomial regression.
iscussion
he present meta-analysis of long-term results after AVR is
he largest conducted in terms of total number of patients,
otal number of deaths, and total follow-up available for
P value
B
b SE P value
.5 0.94 0.082 .4
.001 1.04 0.006 .001
.001 / / /
.01 / / /
/ 1.51 0.24 .01
.11 / / /
mial regression (estimating effect on ratio, biologic/mechanical, of death
ronary artery bypass grafting; b, coefficient; SE, robust standard error. F
f 1 if mechanical valve series and 2 if biologic series. †Entered into modeligure 1. Mean age ()  2 standard deviations (SDs) of the 15
echanical and 23 bioprosthetic valve series. Areas of the
quares are proportional to the total follow-up (patient-y) in each
alve series.igure 2. Total death rate of the 15 mechanical () and 23
ioprosthetic (□) valve series in relation to mean age of each
eries. Areas of the squares are proportional to the total fol-
ow-up (patient-y) in each valve series.ABLE 2. Final regression models of death rate analysis*
redictor variable
A
b SE
echanical vs bioprosthetic valve* 2.34 3.69
igher mean age (per year)† 1.53 0.41
YHA classes III and IV‡ 28.7 7.36
ortic regurgitation‡ 60.0 21.70
oncomitant CABG‡ / /
onstant 46.4 28.3
A, least squares regression (estimating effect on death rate); B, negative bino
ates). NYHA, New York Heart Association’s functional classification; CABG, co
est of final model: P  .0001 for both A and B. *Entered into model with value o(proportion) in individual valve series.
ic and Cardiovascular Surgery ● Volume 132, Number 1 23
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A
CDnalysis. The present setup involves other advantages aimed
t reducing bias. First, we included only series detailing
alves that are currently available for AVR. Second, we
xclusively analyzed series with a maximum follow-up of at
east 10 years to minimize bias especially secondary to low
ates of SVD and related deaths in shorter follow-up bio-
rosthetic valve series. Third, we chose to analyze only
ortality, thus avoiding attempts at correcting for the im-
act of specific valve-related complications with possible
recording bias” especially in regard to bleeding and throm-
oembolism but also SVD in bioprosthetic valve series (cf.
iscussion paragraphs below). Fourth, we managed to cor-
ect mortality differences between mechanical and biologic
alves for the impact of a preoperative measure of heart
isease severity, NYHA classes III and IV, which has to our
nowledge not been achieved before.
The main result of the present analysis is simple and
lear: There was no significant difference in death rate
etween mechanical and bioprosthetic valves when cor-
ected for age and well-known risk factors with no interac-
ion between age and valve type, that is, we could find no
ifference irrespective of age. The strong impact of age,
dvanced NYHA class, and concomitant CABG on mortal-
ty after AVR needs no explanation; these risk factors have
een identified in countless articles. Aortic regurgitation
ad a negative regression coefficient in the least squares
egression model, indicating a reduction in death rate. The
xplanation probably is that age and NYHA classes III and
V had statistically far stronger impact in the model, thus
eaving “young patient in good NYHA class” for aortic
egurgitation. This is strengthened by the fact that we were
esting case series data and not individual patient data:
atients with aortic regurgitation are younger on average
han those with aortic stenosisE2 and will then dominate in
eries with a low mean age. The fact that the regression
odels made perfect clinical sense is an important strength
f our results. It also indicates that correction for important
isk factors is crucial for a meta-analysis to make sense.
We could not analyze the influence of small valve (eg,
revalence of valve size  21 mm) because such data were
vailable in only a fraction of the included valve series
Appendix E1). An impact of prosthetic valve to patient size
ismatch seems to have been noted primarily in studies
ominated by stented porcine valves.17 Small stented por-
ine valves have always been problematic, and many sur-
eons avoid using stented bioprostheses smaller than 23
m, implanting a mechanical valve instead irrespective of
ge.18 Blackstone and coworkers,19 analyzing 13,258 pa-
ients with AVR from several centers, noted that small
ioprosthetic valves that potentially could cause size mis-
atch were rarely implanted. Several of the presently in-
luded bioprosthetic valve series did not include 19-mm
alves.E19,E25,E30,E32 One may thus assume that mechanical b
4 The Journal of Thoracic and Cardiovascular Surgery ● July 2alves often serve as “bail-out” valves for bioprostheses,
hich may compromise some mechanical valve series.
There were only 2 biologic valve seriesE21,E22 with
ubjects with a mean age less than 60 years in whom the
ajority of the mechanical valve series were located,
hich is a weakness of the present study. The group with
young mean age is the group for which one would
specially expect an impact of bioprosthetic valve SVD.
ne of the two “young” bioprosthetic valve series with a
ecent follow-up was small,E21 whereas the other had a
aximum follow-up of only 12 years.E22 In general, the
ncluded bioprosthetic valve series had a mean follow-up
f only 5.3 years, which may be too short to involve an
mpact of SVD-related mortality and thus may have
ignificantly skewed the present results.
There are 2 more problems associated with gauging the
isk of SVD and its impact. Many of the presently included
rticles report only freedom from explant because of
VDE1,E17,E18,E29,E32 or indicate that more than 80% with
VD actually underwent a redo operation.E23,E27,E28 All of
hose studies were retrospective and did not report regular
chocardiographic follow-up, and many patients with SVD
ay thus have been overlooked. In a large 25-year study of
rst-time AVR with allografts, involving annual echocardi-
graphy, from a center renowned for accepting patients for
edo AVR who had been turned down elsewhere, 258 pa-
ients with significant SVD were identified but only 53%
nderwent a redo AVR.20 Furthermore, the 5-year survival
fter the diagnosis of SVD was 78% ( a standard error of
%) with redo AVR but only 33% (5%) without; patients
ho were not offered a redo AVR were on average 12 years
lder and had a 3-fold higher prevalence of concomitant
ABG at the primary AVR than those who were (previ-
usly unpublished analysis by OL). The patients who were
ot offered a redo operation had obviously become too old
r sick with a risk associated with reoperation that was
eemed unacceptably high. Remarkably, the 5-year survival
fter the first appearance of congestive heart failure in the
eneral population is almost exactly similar to the above
oor 5-year survival after unoperated SVD.21 This means
hat freedom from explant (redo) because of SVR tells only
alf the tale, and that SVD is a very serious complication.
ithout a redo operation the prognosis is extremely poor,
ut the risk of reoperation is high with death and serious
omplications in more than 80% of elderly patients22 who
re thus less likely to be given the option. A recent analysis
f 12-year freedom from SVD in first-, second-, and third-
eneration stented bioprosthetic valves indicated that dif-
erences in mean age of the valve series rather than valve
esign was the decisive factor.6 One may thus suspect that
t is not in the best interest of many patients, young in
eneral and old with long life expectancy, to be offered a
ioprosthesis.
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A
CDThe main problem with mechanical valves is the need for
ifelong oral anticoagulant treatment. Bleeding and throm-
oembolism generally account for some 80% of valve-
elated complications associated with bileaflet disc
alves.E2 However, the rate of thromboembolism has in
eneral been halved in aortic bileaflet disc valves compared
ith caged ball valves on similar “old high-intensity” anti-
oagulant treatment.23 A decrease of the international nor-
alized ratio (INR) to the currently recommended level
2.0-3.0) for bileaflet disc valves resulted in a further reduc-
ion in overall complication rates.24 It is well established
hat patient self-management of oral anticoagulation (AC)
reatment manages to keep INR within the desired interval
ignificantly more often than with conventional manage-
ent, which has resulted in a further decrease of complica-
ion rates.25 Two large studies pooling data from 3426 and
627 AC clinics indicated that the risk of bleeding was
elated to the primary indication for oral AC treatment, with
he lowest risk in the group with a prosthetic heart valve and
n INR target of 2.0 to 3.0 and a death rate close to that of
he background population.27
Several pertinent factors may indicte that it would be
xtremely difficult to engage bleeding and thromboembolic
omplications in a meta-analysis of mechanical versus bio-
ogic valve performance. The reported complication rates
ary within the same mechanical valve type, but the vari-
bility is especially high with biologic valves.6 In the
resent bioprosthetic valve series with a mean age of 71 to
4 years and claiming conformance to current guidelines,14
he rates of thromboembolism varied from 1.40% to 6.45%
er patient-year.E18,E20,E26,E30 The bleeding rates ranged
rom nearly nothing to 1.18%/patient-year even though the
uidelines clearly specify that all bleeding events must be
ecorded also in patients who are not on oral AC or anti-
latelet treatment.14 Limited emphasis has traditionally
een put on thromboembolism and bleeding in bioprosthetic
alve series partly because of the dogma that biologic
alves are not thrombogenic and do not require AC treat-
ent, which possibly explains reporting standards. A bio-
rosthetic valve does not protect a patient from the “normal
ccurrence” of, for instance, gastrointestinal, urogenital,
nd cerebral bleeding or from the “background rate” of
troke in general,3,8 which “trickles over into mortality”
hether the authors reported thromboembolism and bleed-
ng or not. Neither does a biologic prosthetic valve protect
he patient from requiring oral AC treatment for the usual
nonprosthetic valve) indications, and more than 20% of
atients have been reported to be taking oral warfarin at a
ean of 2.6 to 5.8 years after AVR.E13,E18,E30 It has been
hown that patients with a beneficial preoperative risk score
btained an age- and gender-specific normal rate of stroke
thrombotic, embolic, bleeding) and normal survival in the
ong term after AVR despite an obsolete mechanical valve
The Journal of Thoracnd high-intensity AC treatment.3 This is in accordance
ith the discovery by Butchart and coworkers28 that nearly
ll patients with an aortic disc valve and a cerebrovascular
vent had at least 1 of the main risk factors for stroke that
re also operational in the general population. This would
ndicate that the composition of a patient material has as
uch or higher impact on the rates of cardiovascular events
s has the valve type. All 3 of the presently included articles
hat abided by the current guidelines14 and compared a
echanical and biologic AVR series with a mean age
reater than 70 years reported similar rates of
hromboembolismE11,E13,E31 and bleeding.E11
Meta-analysis of randomized studies has become the
old standard in evidence-based medicine, but heart
alve research has not lent itself easily to randomization
ecause of the extended time required to get meaningful
esults. Only 2 randomized trials between mechanical and
ioprosthetic valves have been published since 1989: the
dinburgh29 and Veterans Affairs trials.30 Both trials
sed valves that are now obsolete and pooled patients
ith isolated AVR, isolated mitral valve replacement,
nd multiple valve replacement, thus making interpreta-
ions difficult.
onclusion
e found no difference in the overall death rate of
atients receiving either mechanical or bioprosthetic aor-
ic valves irrespective of age. Mortality differences be-
ween mechanical and biologic valves disappeared when
orrected for age and the effect of well-known risk fac-
ors, namely, CABG and NYHA classes III and IV. An
nitial implication may be that choice of prosthetic valve
hould not be rigorously based on age alone. A narrowing
f the gap between mechanical and bioprosthetic valves
n regard to the incidence rates of bleeding and throm-
oembolism because of evolving reporting standards may
hange the concept of valve choice altogether. Biopros-
hetic valve SVD is a worrisome prospect in young and
iddle-aged patients but also in the elderly with a long
ife expectancy. The time-related impact of bioprosthetic
alve SVD, yet to be more fully experienced in all age
roups, may impact even further on future choice of a
rosthetic valve.
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CDppendix E1. Further details of the included valve series
able E1 details the included valve series relative to the specific
rosthetic valve. In a few instances data were extracted from
everal articles detailing the same patient series. We contacted
he corresponding author of articles published between 2000
nd 2004 that potentially could be included but in which es-
ential data were missing and received the requested informa-
ion for 9 articles. Certain valve types have been modified
everal times since their introduction (eg, the Carpentier-Ed-
ards standard porcine valve and Perimount bovine pericardial
alve, Edwards Lifesciences, Irvine, Calif; and the variations of
he St Jude bileaflet disc valve, St Jude Medical Inc, St Paul,
inn) but have retained their original name, whereas others (eg,
orin’s bileaflet and single disc valves, Sorin Biomedica, Mo-
ena, Italy) have been renamed with each change. We chose to
ccept such valve types as current. We included articles origi-
ating in the industrialized world defined as North America,
estern Europe (Sweden, Finland, Norway, Denmark, Ger-
any, Holland, Belgium, Luxembourg, United Kingdom, Ire-
and, France, Austria, Switzerland, Italy, Spain, Portugal, and
reece), Australia, New Zealand, and Japan. The following
ariables could only be extracted from a fraction of the publi-
ations and could therefore not be used in the statistical tests:
revalence of small prosthetic valves (21 mm; 65%), prior
yocardial infarct (50%), diabetes (20%), kidney failure
18%), hypertension (15%), poor left ventricular function
ABLE E1. The included 38 valve series relative to specifi
[Reference] N
echanical valve series
t Jude bileaflet disc, N  10* [E2-E11] 40
ixed disc valve, N  3† [E12, E13] 29
edtronic-Hall tilting disc, N  2 [E14, E15] 15
ioprosthetic valve series
E Perimount pericardial, N  6 [E1, E16-E20] 18
E porcine standard, N  5 [E9, E21-E24] 17
E porcine supra-annular, N  3 [E19, E25, E26] 13
ancock II and MO porcine, N  3 [E27-E29] 16
itroflow pericardial, N  3 [E11, E23, E30] 6
ixed biologic N  2‡ [E13, E31] 6
iocor porcine, N  1 [E32] 
ata are total number of patients and total follow-up of included valve
ccumulated deaths of included series in relation to total accumulated fo
Reference E4, 7% obsolete (Silzone sewing ring). †Reference E12, bilea
bsolete: Edwards Duromedics, and Tekna); reference E12, single disc valv
ileaflet disc valves (St Jude, Sorin, Carbomedics; 0.5% obsolete: Edward
I, Mosaic, Edwards Prima (stentless, 17%); 0.3% obsolete: St Jude X
upra-annular, and Perimount pericardial). The manufacturers for all devic
ileaflet disc valve); Edwards Lifesciences, Irvine, Calif (Carpentier-Edward
dwards Prima stentless porcine valve; Edwards Duromedics, Mira, and Te
edical Carbon Research Institute Inc., Austin, Tx (On-X bileaflet disc v
edtronic-Hall single disc valve; Medtronic Mosaic porcine valve); Shi
iomedica, Modena, Italy (Sorin bileaflet and single disc valves); Sorin Carb
ancouver, Canada (Mitroflow pericardial valve); and St. Jude Medical In
alve; Biocor porcine valve; X-cell porcine valve).13%), and so forth. v
The Journal of Thoracicppendix E2. Details of the statistical analysis
or least squares linear regression, the outcome variable, death
ate, should follow an approximately normal distribution with
niform variance, which was shown to be the case and substanti-
ted by an approximately linear normal plot. Least squares regres-
ion gives the estimated difference between valve types as deaths
er 100 patient-years. The case series were weighted by size using
he total patient-years of follow-up. Negative binomial regression
s a development of Poisson regression, which allows for more
ariation between the series than the Poisson distribution would
llow. This is an approximation because deaths should happen
andomly in time, but in AVR series the death rate is high at the
eginning, decreases after the immediate postoperative period, and
ncreases over the more than 10 years of follow-up as subjects age.
hus, we would not expect a uniform death rate over follow-up,
nd deaths would not be generated by a Poisson process.
We cannot treat study (or article) as a fixed factor, because most
tudies include only 1 series. We therefore adopted a random effects
pproach, treating each study as a cluster and using robust standard
rrors using the Huber-White-sandwich estimator of variance;15 the
ffect is to increase the standard error and reduce power and precision
hen there is more than 1 series of the same valve type (eg, 2 different
echanical valves) in a cluster, and to reduce the standard error and
ncrease power and precision when there are series of different valve
ypes (mechanical vs biologic) in a cluster.
The difference between valve types was adjusted for by
osthetic valve types
patients Total follow-up (patient-y) Death rate %/patient-y
-773) 24,356 (383-6419) 4.35 (1.52-8.88)
2-1755) 17,368 (865-9302) 2.88 (2.48-6.13)
6-816) 12,814 (5120-7694) 4.82 (4.73-4.87)
-589) 9643 (470-2556) 5.81 (4.04-8.30)
-572) 10,465 (862-3375) 5.14 (1.77-6.84)
-1108) 5918 (513-4735) 8.25 (5.52-8.79)
2-843) 10,807 (857-5093) 5.96 (4.94-7.09)
3-403) 2673 (572-1270) 7.48 (5.29-8.90)
3-469) 2726 (349-2377) 8.99 (8.31-9.09)
29 5049 6.28
with range of individual series in parenthesis; death rate is rate of all
p with range of individual series in parenthesis. CE, Carpentier-Edwards.
sc valves (St Jude, Carbomedics, Sorin, ATS, On-X, Edwards Mira; 2.6%
edtronic-Hall, Sorin, Ultracor; 10% obsolete: Björk-Shiley); reference E13,
medics). ‡Reference E13, mixed porcine (CE Porcine Standard, Hancock
reference E31, porcine and pericardial valves (CE porcine standard,
ted are (in alphabetical order): ATS Medical Inc., Minneapolis, Minn (ATS
imount pericardial valve; and Porcine Standard and Supra-annular valves;
ileaflet valves); Koehler Medical Ltd., Lees, UK (Ultracor single disc valve);
Medtronic Inc., Minneapolis, Minn (Hancock II and MO porcine valves;
c., Irvine, Calif (no longer exists; Björk-Shiley single disc valve); Sorin
ics Inc, Austin, Tx (Carbomedics bileaflet disc valve); Sorin Group Canada,
. Paul., Minn (St. Jude bileaflet disc valve; St. Jude Silzone bileaflet discc pr
o. of
69 (93
57 (22
52 (73
52 (75
92 (94
07 (75
45 (13
43 (11
02 (13
10
series
llow-u
flet di
es (M
s Duro
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ley In
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c., Stariables that may influence survival. There are 2 reasons for
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A
CDoing this. A variable that is related to survival and that differs
etween patients given different valve types may either produce
spurious difference between them or mask one that is other-
ise present. For example, patients given mechanical valves
end to be younger with a smaller annual risk of death than
atients given bioprosthetic valves. The second reason for ad-
ustment is that we may have variables that predict survival,
ven though they do not differ between patients given the 2
alve types. Adjusting for such variables will not change the
stimate of the difference between valve types, but will reduce
he random variation and improve the precision of the estimate.
e cannot adjust for all the variables recorded because we have
ata only at the level of the case series, that is, 38, and a good
uideline is that we should have at least 10 observations per
ariable; a regression equation with more than 4 predicting
ariables may be unreliable. Because each series has only 1
ype of valve (mechanical or bioprosthetic), the analysis should
e efficient for estimating the difference between valves. It will
ot be efficient for estimating the effect of other factors. A
ariable that may greatly influence survival at the individual
evel may not produce differences between the case series
ecause too few patients had the adverse characteristic or the
eries did not differ much in the proportion of patients with the
ariable.
We had data on NYHA classes in all articles but in only 5
rticles as mean and standard deviation (SD). We could extract the
roportion of patients in NYHA classes III or IV in all other series.
e calculated the mean and SD from 22 series in which all 4
lasses were given, then used proportion in classes III and IV as
he dichotomous outcome variable and mean NYHA class and SD
s the predictors in a logistic regression. This gave the log odds of
eing in class III or IV, which we converted to a proportion. The
bserved and predicted proportions in NYHA classes III or IV
ere closely and linearly related (r  0.98). We then used the
ame equation to calculate the proportion of patients in NYHA
lasses III or IV in the 5 series in which we only had mean NYHA
lass and SD.
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